The Different Types of Semaglutide Available in the UK

Step 1: understand that 'semaglutide' is a molecule, not a product

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone that signals fullness to the brain, slows gastric emptying, and (in higher doses used for weight management) reduces appetite enough to support meaningful weight loss alongside lifestyle changes. The molecule itself is the same whether it arrives in a pen or a tablet, but the formulation, the licensed indication and the dose schedule differ significantly between the brands built on it.

A useful starting point is the NHS's patient information on semaglutide, which sets out the different preparations clearly. For weight loss specifically, the relevant brands are Wegovy (both formats); for type 2 diabetes, Ozempic and Rybelsus. Confusing them is common, and understandable given the press coverage, but a pharmacist or prescriber will always ask which one you mean and why.

More detail on all the semaglutide preparations licensed in the UK is worth reading if you want the complete picture. This page focuses on the practical differences.

Step 2: the weekly injection, Wegovy pen formats and doses

The Wegovy injection is a once-weekly subcutaneous injection delivered via a pre-filled pen. Prescribers titrate the dose upward roughly every four weeks, starting at 0.25 mg to help the body adjust, then moving through 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, which was for several years the standard maintenance dose. In January 2026 the MHRA approved a 7.2 mg maintenance dose (initially delivered as three 2.4 mg pens in a single weekly injection) and then, on 14 April 2026, approved a dedicated single-dose 7.2 mg Wegovy pen for adults with obesity (BMI 30 or above). The 7.2 mg dose produced around 20.7% average weight loss over 72 weeks in trials, bringing results closer to those seen with tirzepatide at its highest dose.

The injection is kept in the fridge (most people store the current pen in the fridge door so it is easy to spot on the day they need it) but if you are planning a holiday, it is worth reading our guide on taking Wegovy abroad, which covers storage, customs rules and what to carry in your hand luggage.

UK licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. The STEP 1 trial, published in the New England Journal of Medicine, showed around 15% average weight reduction over 68 weeks at 2.4 mg in adults without diabetes. You can explore Wegovy's clinical profile and eligibility criteria in more detail if the injection is the route you are considering.

Step 3: the oral tablet (Wegovy tablets licensed June 2026

On 11 June 2026 the MHRA approved Wegovy tablets as the first oral GLP-1 medicine licensed in the UK for weight management) the first in Europe. This matters for people who are uncomfortable with self-injection, or whose routine makes a daily tablet easier to sustain than a weekly pen.

The tablet formulation uses an absorption enhancer called SNAC to get semaglutide across the gut lining. The dosing ladder for weight management is 1.5 mg, then 4 mg, then 9 mg, building to the 25 mg maintenance dose, with at least a month at each step. Taking it correctly matters: first thing in the morning, on a completely empty stomach, with no more than a small amount of plain water, and nothing else by mouth for at least 30 minutes afterwards. No refrigeration is needed, which makes it more travel-friendly than the injection.

Trial data from the OASIS 4 phase 3 study (307 adults, 64 weeks) showed an average weight loss of around 13.6% compared with around 2.4% on placebo; among participants who adhered fully to treatment, that figure reached approximately 17%. The tablet is not currently available on the NHS (NICE would need to conduct a separate appraisal) so it is a private prescription at the moment. If the tablet is what interests you, our free consultation is where a prescriber can assess whether it is the right type of semaglutide for your circumstances.

Step 4: Ozempic and Rybelsus, what they are and why they are not the answer for weight loss

Ozempic is semaglutide in a weekly injection pen, licensed in the UK for type 2 diabetes. It is not licensed for weight management. Prescribing it for weight loss would be off-label, and the MHRA has been explicit that GLP-1 medicines are not approved for cosmetic or quick weight loss. Despite widespread confusion (driven partly by social media) a regulated UK pharmacy will not dispense Ozempic to someone seeking it solely for weight loss. For more on how Wegovy's licensing differs from Ozempic's, that page covers the distinction in full.

Rybelsus is the oral version of semaglutide licensed for type 2 diabetes, in 3 mg, 7 mg and 14 mg tablets. These strengths are entirely different from the 1.5 mg, 4 mg, 9 mg and 25 mg Wegovy weight-management tablet schedule, and if you want to understand exactly what type of medication Wegovy is and how its classification differs from a diabetes drug, that page explains it clearly.

The cost of private semaglutide treatment varies by provider and by which type is prescribed. How Wegovy is priced privately in the UK covers the context honestly, including what a transparent price should include. For a broader look at weight-loss treatment options beyond semaglutide, that page sets out what is available.